"I wouldnt expect any shift in pricing or anything as a result of this deal," said Richard Purkiss, a managing director at Piper Jaffray. "Pricing is mainly a function of what competition there is, and this doesn't give the company any greater power in most of its categories because they're not par
"Instead of having to play defense and manage through this difficult patent cliff, the company will be able to use additional cash flow to invest in its pipeline, to partner with others or make bolt-on acquisitions," Atlantic Equities analyst Richard Purkiss told Reuters. "The outlook is much bright
Richard Purkiss, an analyst with Atlantic Equities, sees the new blood clot drugs reaching combined global annual sales of $10 billion for stroke prevention and other uses, with Eliquis commanding up to a 60 percent market share, based on data showing it was more effective and safer than warfarin, i
Atlantic Equities analyst Richard Purkiss said Xarelto's prospects have now significantly dimmed. Even if approved, Purkiss said, the drug will now likely only be used if patients do not benefit from warfarin and